Oral Pentoxifylline in Pediatric CAP: Trial Reports Faster Recovery

Key Takeaways

• Over 10 days, adjunctive pentoxifylline was associated with faster normalization of temperature, respiratory rate, and oxygen saturation.
• Inflammatory markers and lung-ultrasound findings also shifted favorably, with fewer involved zones and smaller pleural effusions by day 10.
• Mild gastrointestinal upset was the main reported adverse effect, and the small, single-center, not-double-blinded design used limited assessment time points.

Adjunctive oral pentoxifylline was associated with faster short-term recovery than standard therapy alone in hospitalized children with community acquired pneumonia over 10 days. Respiratory-rate normalization occurred sooner with pentoxifylline plus standard antibiotic and supportive care, averaging 83.3 hours versus 95.7 hours with standard therapy alone, with standard deviations of 18.7 and 25.2 hours. Day-10 laboratory profiles and lung-ultrasound measures also favored the adjunct group.

A single-center randomized controlled superiority study in a tertiary-care pediatric pulmonology unit used 1:1 randomization, a single-blind design with outcome assessors and data analysts blinded. Among 106 hospitalized children with CAP, 53 were assigned to each arm; eligible ages were 2 months to 18 years, mean age was 5.61 ± 3.31 years, and 45.3% were female. CAP eligibility required a lower respiratory tract infection acquired outside the healthcare setting, confirmed by clinical signs and radiographic evidence, and primary outcomes were time to normalization of respiratory rate, body temperature, and oxygen saturation, along with changes in anti-inflammatory biomarkers. Oral pentoxifylline 20 mg/kg/day for 10 days was added to standard antibiotic and supportive therapy, while controls received standard therapy alone.

Temperature normalized in 61.2 ± 11.3 hours with pentoxifylline and 67.4 ± 17.1 hours with standard therapy alone (p = 0.029). Respiratory-rate normalization occurred in 83.3 ± 18.7 versus 95.7 ± 25.2 hours (p = 0.004). Oxygen-saturation normalization occurred in 71.5 ± 26.6 versus 89.0 ± 27.4 hours (p = 0.001). At day 10, respiratory rate was 29.17 ± 4.38 versus 34.02 ± 8.29 breaths/min, and oxygen saturation was 97.28 ± 1.32% versus 96.26 ± 1.55% (both p < 0.001). These comparisons were consistent with faster short-term clinical stabilization in the adjunct arm.

At day 10, the pentoxifylline group also had lower WBC count, LDH, CRP, IL-6, D-dimer, AST, and total bilirubin, with higher hemoglobin and albumin. Lung ultrasound favored pentoxifylline, with fewer involved zones at 3.81 ± 1.75 versus 5.71 ± 2.14 and confluent B-line resolution in 88.7% versus 71.7%. Pleural-effusion size was 0.94 ± 0.60 cm versus 1.65 ± 0.90 cm, while pulmonary complications occurred in 45.3% versus 67.9% and surgical intervention in 26.4% versus 45.3%. Imaging and complication findings moved in the same direction as the clinical recovery endpoints.

Pentoxifylline was well tolerated, and mild gastrointestinal upset was the main reported adverse effect. Broader safety conclusions were limited by the sample size and the adverse-event reporting available here. The authors noted that the study was small, single-center, not double-blinded, and limited biomarker and imaging assessment to baseline and day 10, leaving longer-term outcomes unaddressed.